Search company, investor...
2bPrecise company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

About 2bPrecise

2bPrecise is the developer of a platform that heavy-lifts data then simplifies, condenses, and extracts it. It results in integrated genomic information delivered directly into the user's workflow and harmonized with existing patient data - in any EHR. Plus, it offers semantically stored, research-ready data that can be accessed and acted upon for later study.On August 25th, 2021, 2bPrecise was acquired by AccessDX. The terms of the transaction were not disclosed.

2bPrecise Headquarters Location

Pittsburgh, Pennsylvania,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing 2bPrecise

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

2bPrecise is included in 3 Expert Collections, including Digital Health.


Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

2,275 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.


Clinical Encounter Tech

623 items

Latest 2bPrecise News

2bPrecise, Now Part of AccessDx, Wants to Bridge Genomic Lab Results, Clinical Decision Support

Apr 6, 2022

Premium Save for later CHICAGO – When electronic medical records vendor Allscripts Healthcare Solutions sold 2bPrecise to molecular laboratory and software company AccessDx for an undisclosed amount last August, 2bPrecise went from being a subsidiary of one firm to that of another. But the Pittsburgh-based firm, which integrates genetic and genomic test results into electronic medical records as discrete data, was largely run independently from Allscripts, and AccessDx seems to be taking a similar approach to the asset. 2bPrecise Cofounder and CMO Joel Diamond said that operations have not changed much since the sale, which he described as good for the company. "We need to be an independent space" for interoperability, not connected to an EMR vendor, he said. Allscripts purposely kept 2bPrecise as a separately operated entity to avoid a pitfall EMR vendors have been keenly aware of since Cerner bought clinical decision support content provider Zynx Health from Cedars-Sinai Health System in 2002. Cerner sold Zynx off to media conglomerate Hearst two years later, in part because providers using non-Cerner EMRs were reluctant to work with Zynx. Diamond said that 2bPrecise does not see itself as an interoperability engine for genomics, but he understands the perception. Instead, the firm, founded in Israel in 2015 and now headquartered in Pittsburgh, wants to be the bridge between laboratory-generated genomic information and frontline clinical decision support. "There is a real opportunity to make healthcare better," said Maulik Purohit, associate chief medical informatics officer at Cleveland-based University Hospitals, a 2bPrecise customer. Diamond, who holds an adjunct faculty appointment in biomedical informatics at the University of Pittsburgh and still practices family medicine part-time, said that 2bPrecise wants to be "as close to the sequencer as possible," then cross-reference sequencing results with phenotypic data to make the information clinically actionable. Notably, the AccessDx subsidiary just requires its clients to build a single feed to its technology platform, then handles the interfaces to individual labs. In doing so, 2bPrecise presents the information within clinician workflows in multiple brands of EMR. Small practices, especially in primary care, are still on kind of a treadmill, where they have to see dozens of patients a day as quickly as possible for financial reasons and don't really have time to stop and think about genomics. If there is a genetic test in a patient's record, many do not know what to do with it. "This is our problem to solve, [putting] that in the workflow, making it easy," Diamond said. "Every time I go to prescribe a medicine, it's in my workflow, inside my EMR. I see those results and now I'm always thinking about it." The Patient Protection and Affordable Care Act mandates that US health insurance companies pay for preventive care, including an annual physical, and doctors typically order chemistry profiles and lipid panels during such exams. For someone who has had excellent cholesterol numbers several years in a row, "doing a lipid panel every year is absolutely worthless," Diamond said. "The cost of doing that lipid panel is the same cost as doing a PGx test, which you do once and extrapolate over" for the rest of the patient's life. "As a primary care doctor, this is hard," Diamond said. Technology can help capture family history as discrete data, then feed algorithms to suggest appropriate genetic testing that physicians likely are not thinking about. "This is the holy grail of clinical decision support, but it's far too little, too late that genetics is part of it," Diamond said. There is some uptake of pharmacogenomics among specialists, such as oncologists looking for the right chemotherapy. But the same oncologists might not know about the pharmacogenomic component of prescribing anti-nausea drugs, pain medications, or antidepressants, Diamond said. "Even people that have comfort within precision medicine within their subspecialty, it tends to be very narrow," Diamond added. "This data needs to be liberated to everybody in the organization because it is 'test once and query often'." University Hospitals uses an Epic Systems EMR. Despite the former Allscripts ownership, 2bPrecise can interface with Epic, Cerner, Meditech, Athenahealth, eClinicalWorks, Greenway Health, and other major EMR vendors, including Allscripts. "I think [Epic] is very good at some of the technical back-end stuff with the genomics in the sense that they might be able to make a feed" to a lab, Purohit said. However, it requires the organization to build interfaces with each lab it works with. "It is an immense amount of work for a health system to do and maintain," he said. "If our IT stuff is burning and churning hours to maintain all those data feeds to all those different labs, that's hours that we can't use to innovate and move ahead" in patient care, Purohit added. "Our staff now is freer to handle higher-level functionality." Purohit also serves as the health system's innovation lead for transformation. In that role, he educates healthcare providers on how best to use technology, including the 2bPrecise platform. Another issue is that clinicians generally do not want or need raw genomic data. 2bPrecise curates data and presents it in a way that Purohit said can be used for clinical decision support. University Hospitals started with 2bPrecise in cancer and has since expanded to reproductive health on its own, without any push from the vendor, thanks to clinician demand, according to Diamond. "A concerted effort to do pharmacogenomics across the enterprise is the next piece," he added. 2bPrecise sends a flow of discrete genomics data back to University Hospitals' Epic installation, which the health system sets up as clinical decision support in the clinician workflow. Diamond said that it is largely a workflow problem. Primary care physicians are unsure what to do with genomic information, particularly if results come back from the lab as a PDF file that is not machine-readable and thus cannot inform automated clinical decision support. Purohit said that University Hospitals is seeing substantial growth in demand for genetic counseling. Since adopting 2bPrecise, the organization has been able to give more targeted advice, to the level consumers have gotten accustomed to. "If you go to Netflix, they have data on every movie you watch," Purohit said. "If you go to Google, they complete my searches even before I do. They write half my emails. And so I think in today's world, that level of sophistication is the expectation." Diamond noted that University Hospitals has looked at its use of 2bPrecise not as a genomics project or a data project, but rather a clinical exercise. For example, he said the health system is applying pharmacogenomics to address what he called treatment-resistant depression, namely patients who have had little or no success on multiple antidepressants. "Now they know that those patients probably have failed multiple treatments because they were on the wrong drug," Diamond explained. "So they're not approaching this as either a technical or a genomics problem. It's just part of an initiative they have in identifying those patients." Diamond also said that 2bPrecise has a module for addressing severe drug-gene interactions in polypharmacy patients, many of whom are elderly. The company wants to make the process of identifying patients with such interactions opaque to physicians. "The doctor should probably not think of this as a genetic problem. It should fit into existing problems they have," Diamond said. Many physicians, he said, were not trained in genetics and see genomics as a series of yes/no questions, when it really is a continuum. The technology also helps an organization like University Hospitals scale its clinical genomics program by not having to refer every case to a geneticist, he said.

2bPrecise Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

2bPrecise Rank

  • When was 2bPrecise founded?

    2bPrecise was founded in 2016.

  • Where is 2bPrecise's headquarters?

    2bPrecise's headquarters is located at Pittsburgh.

  • What is 2bPrecise's latest funding round?

    2bPrecise's latest funding round is Acquired.

  • Who are the investors of 2bPrecise?

    Investors of 2bPrecise include AccessDX.

  • Who are 2bPrecise's competitors?

    Competitors of 2bPrecise include LifeOmic.

You May Also Like


Verantos specializes in high accuracy real-world evidence (RWE) generation. The Verantos RWE platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for regulatory and reimbursement use. The Verantos RWE platform leverages data science and artificial intelligence along with advanced data sources to generate RWE capable of supporting clinical assertions.

Syapse Logo

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.

Ignite Data Logo
Ignite Data

Ignite Data helps access the right patients and data for UK clinical studies and database projects.

Validic Logo

Motivation Science is the developer of Validic, a digital health platform that provides a simple connection to secure, standardized data from specialized digital health technologies, such as wellness applications, wearables, fitness equipment and clinical devices.

Datavant Logo

Datavant is dedicated to accelerating the discovery, development, and commercialization of new medicines through machine learning. It aims to partner with biomedical research institutions to eliminate silos of information and unlock insights from healthcare data. The firm was founded in 2017 and is based in San Francisco, California.

Owkin Logo

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology. The company was founded in 2016 and is based in New York, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.